What DBV Technologies (DBVT) Said on Its Q3 Earnings Call

Key Points

• DBV Technologies submitted a BLA to the FDA for VIASKIN Peanut in children ages 4 to 7 and requested priority review, though the FDA has not yet ruled on that request.
• Manufacturing readiness remains a key issue because contract manufacturer Fareva Amboise is remediating an FDA warning letter. DBV expects to be ready for a potential pre-approval inspection by Feb. 1, with mock inspections planned beforehand.
• DBV ended Q3 with $165.7 million in cash, enough to fund operations into Q3 2027, while increasing spending on clinical programs and preparations for a potential U.S. launch. A separate toddler BLA for ages 1 to 3 is expected in 2027.

DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a potential commercial launch and addressing manufacturing readiness at its contract manufacturing partner.

Chief Executive Officer Daniel Tassé described the filing as the principal achievement of the third quarter of 2026. He said the company is working with the FDA during the review process and has requested priority review for the application. The FDA has not yet made a decision on that request.

“All of our planning, whether it is launch planning or whether it is remediation in preparation for the PAI, is all hinged on what would be a priority review,” Tassé said, referring to the pre-approval inspection, or PAI. He added that the company believes it can manage its preparations within a priority-review timeline.

Manufacturing remediation and inspection preparation

A major topic of the call was an FDA warning letter issued in April 2026 to Fareva Amboise, DBV’s contract manufacturing partner. The letter followed a September 2025 FDA inspection related to the manufacturing of a veterinary product and an aseptic manufacturing process at the site. DBV said the warning letter also included observations involving quality-management operations and systems, giving it site-wide implications.

Kevin Malobisky, DBV’s chief operations officer, said responsibility for remediating the warning letter rests with Fareva. Fareva submitted its written remediation plan to the FDA within 15 business days and has since provided monthly updates to the agency, according to Malobisky.

DBV’s manufacturing and quality teams are working with Fareva and third-party consultants on aspects of remediation relevant to VIASKIN Peanut production. Malobisky said Fareva shared its detailed project plan with DBV, giving the company “direct access and line of sight” into the work most applicable to the patch.

DBV emphasized that the BLA review and Fareva’s warning-letter remediation are separate processes, though they converge in the FDA’s pre-approval inspection of the manufacturing site. The company included a target date for PAI readiness in its BLA that falls after Fareva expects to complete its remediation work.

During the question-and-answer session, Tassé said Fareva shares a substantial amount of its monthly reporting with DBV, although it does not provide all information because the facility serves approximately 70 customers and makes about 100 products. He said an FDA reinspection has not yet been scheduled.

Malobisky said DBV is comfortable with Fareva’s remediation progress and with the timing buffer between anticipated remediation completion and the PAI. DBV has told the FDA it expects to be ready for inspection by Feb. 1 and said mock inspections will occur before then.

The company also plans to establish a second manufacturing unit to support capacity in later years, Tassé said. However, he noted that establishing a new facility, whether through a contract manufacturer or a company-owned site, takes roughly three years and is not intended as a near-term backup plan for Fareva.

Toddler BLA expected in 2027

DBV also discussed its development program for children ages 1 to 3. The FDA previously provided written communication confirming an accelerated-approval pathway for VIASKIN Peanut in toddlers, the company said.

Management said it has discussed a potential rolling submission with the FDA but agreed with the agency that the toddler BLA review should begin shortly after the review of the 4-to-7-year-old application. Both submissions would be reviewed by the same FDA team, and DBV said a sequential process could allow the agency to build on the earlier review while avoiding a potential review bottleneck.

DBV expects to submit the toddler BLA in 2027, subject to continued discussions with the FDA on submission format, content and timing.

Chief Medical Officer Pharis Mohideen said enrollment in the COMFORT Toddlers supplemental six-month safety study ended in the second quarter. He characterized the study as a safety-exposure study rather than a trial with a primary efficacy endpoint. DBV expects to announce results after they are available, with Mohideen saying the company does not expect safety findings that would differ from the product’s historical profile.

Cash runway and commercial investment

Chief Financial Officer Virginie Boucinha said DBV ended the third quarter with $165.7 million in cash and cash equivalents, including $50 million in gross proceeds from sales of American depositary shares to RA Capital through its refreshed at-the-market program.

Following the BLA filing, the company updated its operating and liquidity forecast and said existing cash is expected to fund operations into the third quarter of 2027.

Year-to-date operating expenses totaled $164.4 million, compared with $107 million in the prior-year period. Boucinha said roughly half of the increase supported clinical and regulatory work for the BLA, including ongoing work on COMFORT Toddlers, its open-label extension, the VITESSE open-label extension and THRIVE. The other half supported the company’s transition toward commercial readiness.

• Sales and marketing expense increased to $15.7 million from $1.9 million a year earlier.
• DBV is investing in medical affairs, market access, marketing, account management, pharmacovigilance and launch infrastructure.
• The company is also building pre-commercial inventory and expanding corporate functions intended to support commercialization.

Tassé said DBV is considering a U.S. sales force of roughly 50 to 70 representatives to target approximately 4,500 allergists. The company is also conducting payer discussions through account managers and working on health-economic and access considerations. Management did not provide first-year sales guidance for VIASKIN Peanut.

About DBV Technologies (NASDAQ:DBVT)

DBV Technologies SA NASDAQ: DBVT is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies' lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.